GlassScriptPhysician profile
Thomas A Neal
NPI 1922079235
$3,672.97
in general payments reported to CMS, 2019-2025
35 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $355 · 2021: $979 · 2022: $571 · 2023: $498 · 2024: $473 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,034.41 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $568.99 | 2021-2025 | |
| Amgen INC. | $242.28 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $227.26 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $173.03 | 2019-2022 | |
| Exact Sciences Corporation | $137.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $134.20 | 2021-2023 | Gvoke Hypopen |
| Pfizer INC. | $114.95 | 2019-2024 | |
| Novo Nordisk INC | $113.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.49 | 2020-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $70.74 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $54.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.70 | 2022 | |
| Genentech USA, INC. | $51.30 | 2020-2021 | |
| Boston Scientific Corporation | $50.84 | 2021-2025 | Watchman Flx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $47.64 | 2019-2020 | |
| Horizon Therapeutics Plc | $45.53 | 2020-2023 | Krystexxa |
| Dexcom, INC. | $45.53 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $44.88 | 2025 | Omnipod |
| Beta Bionics, INC. | $43.57 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sunovion Pharmaceuticals INC. | $42.07 | 2019 | |
| Eisai INC. | $40.61 | 2020-2021 | |
| Corcept Therapeutics | $36.31 | 2021 | |
| Edwards Lifesciences Corporation | $28.06 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi Pasteur INC. | $22.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.29 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.36 | 2020 | |
| Medtronic Vascular, INC. | $16.36 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.33 | 2025 | Voquezna |
| Allergan, INC. | $15.58 | 2020 | |
| Vanda Pharmaceuticals INC. | $13.71 | 2022 | |
| Merck Sharp & Dohme LLC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Neal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.